{"ticker": {"uuid": "21d876a3-0a16-4768-b968-9053e6ce791b", "symbol": "LENZ", "name": "LENZ Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely", "summary": "LENZ Therapeutics (NASDAQ:LENZ) had US$258m in cash by March 2026 and burned through US$87m in the last year, giving it a cash runway of about 3.0 years. While its cash burn increased significantly by 68% in the last year, analysts expect the company to reach cashflow breakeven b", "url": "https://www.sahmcapital.com/news/content/were-hopeful-that-lenz-therapeutics-nasdaqlenz-will-use-its-cash-wisely-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:42:17", "published_display": "16 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions", "summary": "Analysts have revised the fair value estimate for LENZ Therapeutics (LENZ) from US$53.71 to US$32.00, reflecting a reset in growth assumptions. While some analysts maintain a bullish stance on long-term prospects, others express caution due to execution risks and valuation concer", "url": "https://finance.yahoo.com/markets/stocks/articles/lenz-therapeutics-lenz-stock-fair-081728327.html", "source_name": "Market source", "published_at": "2026-07-11T08:09:54", "published_display": "11 Jul 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia", "summary": "LENZ Therapeutics has launched a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform offers convenient online evaluations by independent licensed eyecare providers, e-pharmacy prescription fulfillment, and home delive", "url": "https://www.visionmonday.com/eyecare/article/lenz-therapeutics-launches-vizz-telehealth-prescribing-option-for-the-treatment-of-presbyopia", "source_name": "VisionMonday.com", "published_at": "2026-07-08T12:18:00", "published_display": "08 Jul 2026 12:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNdFJtY0JaZVUxamdqSGdTd20zT2RRbGs3Xzc2VlcwS25PaHpDb3p6TFdUNHhsUExjTlRKbF9RTHZmMS1CTUVydkktajdaYy1iemRJMXhHRGhHVUJWb3kxc2VRSzdRTU5BZXNwa1lGU1JmYnp5OHhzbUUwNUxzc214bEFNUUFxQWI3RkVXZHJBbm5BWEdwZnYxZHRnSmtRc0I0TkdHWi1sa1FsS2twQUxYdFpad1pwSDlHcGF2a0c4cGFtTW5sODFlY3VZdTVZQUdnZVE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T12:26:50+00:00", "published_display": "07 Jul 2026 12:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform allows patients to receive online evaluations from licensed eye care providers, prescription fulfillment, and home deliver", "url": "https://ir.lenz-tx.com/news-events/press-releases/detail/59/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-option-to-accelerate-patient-access-to-vizz-for-the-treatment-of-presbyopia", "source_name": "LENZ Therapeutics", "published_at": "2026-07-07T05:11:23", "published_display": "07 Jul 2026 05:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ\u00ae for the Treatment of Presbyopia", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ\u00ae (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform, accessible via VIZZ.com, allows patients to consult with independent licensed eye care providers online, receive prescri", "url": "https://finance.yahoo.com/healthcare/articles/lenz-therapeutics-announces-launch-telehealth-121500014.html", "source_name": "Market source", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ lets eligible patients get VIZZ online, with home delivery", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ aceclidine ophthalmic solution, designed to treat presbyopia. This platform, accessible via VIZZ.com, connects patients with licensed eye care providers for online evaluations, e-pharmacy prescription", "url": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-en9ui0god8io.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:41:07", "published_display": "06 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign", "summary": "LENZ Therapeutics has launched telehealth accessibility for its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, allowing patients to receive online evaluations, e-pharmacy prescription fulfillment, and home delivery. This initiative coincides with a national ad", "url": "https://www.quiverquant.com/news/LENZ+Therapeutics+Launches+Telehealth+Access+for+VIZZ+Alongside+National+TV+Campaign", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T12:20:00", "published_display": "06 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ - LENZ Therapeutics Inc Options", "summary": "This article provides comprehensive financial data for LENZ Therapeutics Inc. (LENZ), including its last closing price, market capitalization, income, sales, and various financial ratios. It also details insider and institutional ownership, stock performance metrics, and analyst ", "url": "https://finviz.com/stock?t=LENZ&p=m&ty=oc&b=2&r=y5&ov=list_strike&s=7.5", "source_name": "Finviz", "published_at": "2026-07-03T04:40:04", "published_display": "03 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ)", "summary": "LENZ Therapeutics announced changes to its Board of Directors and Audit Committee following the resignation of director Zach Scheiner on June 30, 2026. Scheiner's departure was not due to any dispute, and the Board subsequently reduced its size to six members. Additionally, Jeff ", "url": "https://www.stocktitan.net/sec-filings/LENZ/8-k-lenz-therapeutics-inc-reports-material-event-35e417be9a1c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:40", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article focuses on the \"Price to sales forward\" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It appears to be a financial data snippet from TradingView, providing an overview of the company's stock performance. The content includes general market information and links ", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:39:42", "published_display": "01 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides a brief financial update on LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its price-to-book forward ratio. The content indicates the market is currently closed, with no trades, and offers information on the company's financials, news, and ", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T02:39:13", "published_display": "01 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides financial information for LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial snapshot from TradingView, detailing various data points and market information relevant", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:10:34", "published_display": "30 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides the \"Price to earnings forward\" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It's presented within the context of TradingView's financial data offerings for the company. The page focuses on a specific financial data point rather than a detailed analyti", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:09:38", "published_display": "30 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index", "summary": "LENZ Therapeutics, Inc. (NasdaqGS:LENZ), a biopharmaceutical company focused on developing treatments for presbyopia, has been added to the Russell Microcap Value Benchmark Index. This news follows a period of significant activity for the company, including recent license agreeme", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af020", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:38:00", "published_display": "29 Jun 2026 16:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark", "summary": "LENZ Therapeutics, Inc. (NasdaqGS: LENZ) has been added to the Russell 2000 Value Benchmark Index. This news follows several recent updates for the biopharmaceutical company, including its addition to the Russell Microcap Value Benchmark and an exclusive licensing agreement for i", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-added-to-russell-2000-value-benchmark-ce7f5fdfd880f320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:09:38", "published_display": "29 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "LENZ Therapeutics, Inc. (NasdaqGS:LENZ) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows a previous report that the company was also dropped from the Russell 3000 Growth Benchmark. The company, which is a pre-commercial stage biopharmaceutical ", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdede88f022", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:44:12", "published_display": "29 Jun 2026 09:44", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a shared voting and dispositive power over 1,603,512 shares, or 5.1%, of LENZ Therapeutics, Inc. Common Stock. This disclosure was made via a Schedule 13G filing, indicating a passiv", "url": "https://www.stocktitan.net/sec-filings/LENZ/schedule-13g-lenz-therapeutics-inc-passive-investment-disclosure-5-01a6539f771d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:02", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ)", "summary": "This article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report details. The company's", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:03", "published_display": "26 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst", "summary": "LENZ Therapeutics has signed an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its FDA-approved eye drop therapy, VIZZ, targeting presbyopia in Australia and New Zealand. This marks LENZ's fifth such international partnership, with an analyst", "url": "https://www.sahmcapital.com/news/content/lenz-therapeutics-eye-drug-profile-supports-blockbuster-opportunity-analyst-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-26T01:10:38", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand", "summary": "LENZ Therapeutics, Inc. has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia treatment, VIZZ, in Australia and New Zealand. LENZ Therapeutics will receive an upfront payment and a significant share of gross pr", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-and-arrotex-pharmaceuticals-pty-ltd-announce-exclusive-license-and-commerci-ce7f5fd8dc80ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T12:11:19", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com", "summary": "LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to register and commercialize its presbyopia drug VIZZ in Australia and New Zealand. LENZ will receive an upfront payment and profit share from sales of VIZZ, a once-daily eye drop that received FDA approval i", "url": "https://za.investing.com/news/stock-market-news/lenz-licenses-presbyopia-drug-vizz-to-arrotex-for-australia-nz-93CH-4342014", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T02:41:35", "published_display": "25 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ\u2122 in Australia and New Zealand", "summary": "LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ\u2122 eye drops in Australia and New Zealand. This partnership will see Arrotex, Australia\u2019s largest pharmaceutical company, register and commercialize VIZZ, L", "url": "https://ir.lenz-tx.com/news-events/press-releases/detail/58/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-commercialization-agreement-for-vizzin-australia-and-new-zealand", "source_name": "LENZ Therapeutics", "published_at": "2026-06-25T01:40:21", "published_display": "25 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand", "summary": "LENZ Therapeutics (NASDAQ:LENZ) has finalized an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its presbyopia treatment, VIZZ, in Australia and New Zealand. This partnership provides LENZ with an upfront payment and a significant share of gr", "url": "https://grafa.com/en/news/united-states/lenz-therapeutics-arrotex-vizz-license-australia-new-zealand", "source_name": "grafa.com", "published_at": "2026-06-24T16:40:38", "published_display": "24 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ", "summary": "LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia drug, VIZZ, in Australia and New Zealand. LENZ will receive an upfront payment and a profit share from sales of VIZZ, a once-dail", "url": "https://www.investing.com/news/company-news/lenz-licenses-presbyopia-drug-vizz-to-arrotex-for-australia-nz-93CH-4758164", "source_name": "Investing.com", "published_at": "2026-06-24T13:40:38", "published_display": "24 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Arrotex Pharmaceuticals Announce", "summary": "LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ\u2122 in Australia and New Zealand. This agreement will allow Arrotex to register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for pre", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316833/0/en/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-commercialization-agreement-for-vizz-in-australia-and-new-zealand.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T12:40:38", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ expands VIZZ beyond the U.S. with Australia, NZ deal", "summary": "LENZ Therapeutics has partnered with Arrotex Pharmaceuticals for the exclusive license and commercialization of VIZZ, their FDA-approved presbyopia eye drop, in Australia and New Zealand. This agreement is LENZ's fifth ex-U.S. commercialization deal for VIZZ and includes an upfro", "url": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-8yzvuv409ovj.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:39:39", "published_display": "24 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions", "summary": "LENZ Therapeutics (NasdaqGS:LENZ) is forecast to grow earnings and revenue significantly, but is expected to remain unprofitable for the next three years, with projected negative return on equity. Recent analyst revisions show decreased revenue forecasts and increased loss projec", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-24T12:39:39", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of LENZ Therapeutics Inc (LENZ), stating its current valuation score is 6.79, ranking it 297 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio is -1.74, significantly below its recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lenz/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:57", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of LENZ Therapeutics Inc (LENZ), focusing on its support and resistance levels, key indicators, and moving averages. The stock's current price momentum score is 6.40, ranking it 263 out of 388 in its industry, and it is trading between a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lenz/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:57", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics adds China partner for presbyopia drug VIZZ", "summary": "", "url": "https://finance.yahoo.com/m/0753ae60-922c-3a72-a870-1d6137c9c4da/lenz-therapeutics-adds-china.html", "source_name": "Proactive", "published_at": "2026-06-08T15:33:00+00:00", "published_display": "08 Jun 2026 15:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-receive-vizz-payments-080136167.html", "source_name": "MT Newswires", "published_at": "2026-06-08T08:01:36+00:00", "published_display": "08 Jun 2026 08:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ\u00ae (LNZ100) in Greater China", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-announces-everest-medicines-233000707.html", "source_name": "GlobeNewswire", "published_at": "2026-06-07T23:30:00+00:00", "published_display": "07 Jun 2026 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China | LENZ Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQMFNudDVLc1pmQUU1YzZTbm1UNzRVYWdoWFFreWFJMDZRSWtfNVdLbUdRNnN1cmxyZWlpWGxQaHZlMVNyVXF6NHNsYmVWRXNUcWtlUzlFemlLblR2bmlUd1BVcmdZQW1tejJmSDUyd1czS1Z3WTMwWDkxTjVjY1RQeHNieU85ZTQ2ZWVZRTB5TjRlWm1sOWIyUENiMEM2UTZnWlNhdTFib00zbjN2YTBMTXMwRzJSVHcyLTJCckh3T241Y3ptWVF3OVY4dFk1bjdUeDVNQnpZaFhTMFFiZ0RMekNXVGRlVktvXzhtU0Ffa1VVbm9o?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-participate-upcoming-investor-120000333.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc25sWHE5ZmNLbFh2Q0JQSjZMWllCb2RYN0VoMGI5TEljMHpDc1ZGbnZrOERkYUx2TDYxUHd0VFpxZE52MXZ6Wk1yYjdTck5IWkFaQUM3NkFseEpUQWx2ampkUkZzRUZPa0paUkdGcWZhVTJKTmJ4bXdST2w1RUxwcFJfalpaMXNaSHNxaTNtVXRJbEtqbEVrV05HMzNkdUl1?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNV29hSU5Zd2oyQWNSV005OTNYSFp4RnpMYU1BSVZ3dUYzLWZPNGRaNVdLWklMcFZDVEhGZEhkc2lFSzVWN25PMmE4X0tMV216bUhmRWpMYnlPNzlRdlZJRUlDeG5ZaWdTLXJUQ09Od2U1czkyRThCSXlETGZCMWwwTXVrNzlYU09Uci1ObUdQQXAxb2NZS0JnUllGV2xYRjA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOZHJ0NFY5Ymc3Z2VGd2tSRGVIMGpnSG0yOTVkamVwZm1KU0RSSkx5RUtsUnh4M1RoMUtjeFlKQU5IZG9zMUwwS3Y1NUhpaE81Z1JRSGEwWkQyUUN6RUtzcWwzbnlpaWl5WnFLWGhQUmFJc3p1MUNqN3JGSFIzbGlHS3BReWN5S2VmV1pYXzdLazk4b0k1SlB1c21IQ1ZqV2tRYUQwdHNTcURwMVVaQW8xN1JmcmdKcE9DaTVLZU9VcXlaRjNVb3pjUDd4Ni1YTVlacU9jQVJIMXVCaG1mM042OFQ3bHdteXFqMkE?oc=5", "source_name": "LENZ Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ THERAPEUTICS ($LENZ) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQjlDaGI4MEpmMWxWRlluYzduZmE4NTdZVlFGaGV0NGUxNXIxcU54Vkh4WWxPaHpjTWF1MDBTcnlzUmJXS1RfTlB3Y1NrTDRRU3hpNW80WTQ2eWpxaWZpZmc4N0ZqSWJYSE5ZZVZwQ2tuRVNCSFlVZnVrLUtJYkk1RUVhb0dkcDlGaldkOGRVX2Ita21t?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPR2RsdHJDQWVjYk9iaGFWQ0I2SjdHQ05HV2w1S09VclU4OWU2Qzk2VXU4WjdwZmd4TWt5eldmcDhWVnFFdld5ZnN0TG9ZVnRKSlBXVVpNRU91VzN1Z3E3SDlsdk5ESFY4QzhWUlNSZzdHd0plSW1zYXM5OXVoRTE4MmoxV0JmUTlVdmNGd3dUY2pqVXhPTHFmQnpBc1phdmQ3X0FxRXVR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LENZ Therapeutics: Speculative But Strong Buy (NASDAQ:LENZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOS2VLNFdLamNidU9EaVc3NnVrZEFMQk1WUUpfbktiMFUxNkNDcXNxUHdTbU5HV1dHaVZJVXJuV0xwNms1c0N4TnNhZzVhWklNUTdEZi1GWVA2bGZSSER2ZFVzUlJxTkVMN2l6ejNxUmZoZ2FNSUZkUVlGNFJJUGo2XzFZWVdvMS1UOXBKWU5B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of LENZ Therapeutics Picks Up 57% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNMlFsVDVnZzc0Q0o5NEt4RmdJTjk1ZTYtLVpIaVgzTGt6R0g1UzV6cFNVamdsVmVpT3VrT1d2SlpRWHI0YkNmaS1CVnN2cTZiX09manpvc2YtemluY0ZFYW5YSHEyd1ZIYXd0NEVMdDRMdWgxM0kwazgxb0ctT1Mta3Yyd29ZMU9JSEZBeFBQNDZRVjc4WVhzaV9ZYUxhRGhtbE5F?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxObEFWWU4yLUJMMndaaS1aeTEtdWQzX1d2elpabmw2dWpkQkZmMFpyVjB4SjVKMFhmMWI0QUU2bEZ5Wm8wUHhWX2N6N0R3c2JEUUZ5aW1vSy1kS0VHN0kzQ1RCSWM4SWhsVzhaQkJ0NUFEQmsyMlpqYXhYcUp4VERRQTB5MmZRZUNqUVVjTE16ZlRMVnNicXJZ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics (LENZ) Loss Deepens As VIZZ Launch Tests Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lenz Therapeutics Stock Crashed Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNVnBaSHV1NzBaN2xQWTNBc18tS1Y1Tml4emVWQ0d0Q1pqaDl1c1c2Q0pwNzNHRUd0MmZFc2lpeFphVjFHaldGMjBteHhHNDNlaDlVdlhfeHZOM1ctcDhlU1ktV24yZUQ3SllyWnFCT24yRkZxSGhsd3pWYlNPaXlGdHhfNUJ2d1pFUDB6Zw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At LENZ Therapeutics (LENZ) Valuation After New Middle East VIZZ Distribution Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOUmhsbmg0TzF5NjJXbHctWWV1aEdfZVJMU3pyYmdQaEJncnhMSlgxaDhWSDJEempZQWxab0dHNldHd0hTQ2ppdHMwVjZqaEw2MENncTVGMThCTGxrOFNNLXhDamFnb0k2TkNJXzNYQ1NsMkVTTFQ0OVo3UHFDbk0zUUlaNWVMNndnZWlHMzN4eGxDQ0ZnMXNWVm9pQ1BLZ25BX2ptVHZXUXRtQmFXM296bUdKazMyUk1uMGlRY0R5QW9IcGdyRXB6TzJSaEhFZGZUaUZEWVN3UkMyYjZ2WHg2WldSbWhnVUxKelZobGRfMTZtQ1hVdExyamM4RXNFc0xuYVFJaw?oc=5", "source_name": "LENZ Therapeutics", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics: Was That A Market Overreaction? (NASDAQ:LENZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOMTZyS2ZObm9XeFhhMW5ZZllscnZNeHNZUmNTUHhMQjE5M2NnQ25qaldfblNCZXV2S0JBYUtJN2FFbmpoak1zRXctSlpTNXJqdWZ2LWtuT042YnBwN1V6SEdlbHlUY1FRMno4MjBENmt4RjA2ODAwbE8tTU92Zjk2dmxqeHFfWUZyUmZqamV3MHpxVUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely", "summary": "LENZ Therapeutics (NASDAQ:LENZ) had US$258m in cash by March 2026 and burned through US$87m in the last year, giving it a cash runway of about 3.0 years. While its cash burn increased significantly by 68% in the last year, analysts expect the company to reach cashflow breakeven b", "url": "https://www.sahmcapital.com/news/content/were-hopeful-that-lenz-therapeutics-nasdaqlenz-will-use-its-cash-wisely-2026-07-15", "source_name": "Sahm", "published_at": "2026-07-16T10:42:17", "published_display": "16 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions", "summary": "Analysts have revised the fair value estimate for LENZ Therapeutics (LENZ) from US$53.71 to US$32.00, reflecting a reset in growth assumptions. While some analysts maintain a bullish stance on long-term prospects, others express caution due to execution risks and valuation concer", "url": "https://finance.yahoo.com/markets/stocks/articles/lenz-therapeutics-lenz-stock-fair-081728327.html", "source_name": "Market source", "published_at": "2026-07-11T08:09:54", "published_display": "11 Jul 2026 08:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia", "summary": "LENZ Therapeutics has launched a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform offers convenient online evaluations by independent licensed eyecare providers, e-pharmacy prescription fulfillment, and home delive", "url": "https://www.visionmonday.com/eyecare/article/lenz-therapeutics-launches-vizz-telehealth-prescribing-option-for-the-treatment-of-presbyopia", "source_name": "VisionMonday.com", "published_at": "2026-07-08T12:18:00", "published_display": "08 Jul 2026 12:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Buy on LENZ Therapeutics stock on telehealth launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNdFJtY0JaZVUxamdqSGdTd20zT2RRbGs3Xzc2VlcwS25PaHpDb3p6TFdUNHhsUExjTlRKbF9RTHZmMS1CTUVydkktajdaYy1iemRJMXhHRGhHVUJWb3kxc2VRSzdRTU5BZXNwa1lGU1JmYnp5OHhzbUUwNUxzc214bEFNUUFxQWI3RkVXZHJBbm5BWEdwZnYxZHRnSmtRc0I0TkdHWi1sa1FsS2twQUxYdFpad1pwSDlHcGF2a0c4cGFtTW5sODFlY3VZdTVZQUdnZVE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T12:26:50+00:00", "published_display": "07 Jul 2026 12:26", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform allows patients to receive online evaluations from licensed eye care providers, prescription fulfillment, and home deliver", "url": "https://ir.lenz-tx.com/news-events/press-releases/detail/59/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-option-to-accelerate-patient-access-to-vizz-for-the-treatment-of-presbyopia", "source_name": "LENZ Therapeutics", "published_at": "2026-07-07T05:11:23", "published_display": "07 Jul 2026 05:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ\u00ae for the Treatment of Presbyopia", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ\u00ae (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform, accessible via VIZZ.com, allows patients to consult with independent licensed eye care providers online, receive prescri", "url": "https://finance.yahoo.com/healthcare/articles/lenz-therapeutics-announces-launch-telehealth-121500014.html", "source_name": "Market source", "published_at": "2026-07-06T18:10:33", "published_display": "06 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ lets eligible patients get VIZZ online, with home delivery", "summary": "LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ aceclidine ophthalmic solution, designed to treat presbyopia. This platform, accessible via VIZZ.com, connects patients with licensed eye care providers for online evaluations, e-pharmacy prescription", "url": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-announces-launch-of-new-telehealth-prescribing-en9ui0god8io.html", "source_name": "Stock Titan", "published_at": "2026-07-06T12:41:07", "published_display": "06 Jul 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign", "summary": "LENZ Therapeutics has launched telehealth accessibility for its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, allowing patients to receive online evaluations, e-pharmacy prescription fulfillment, and home delivery. This initiative coincides with a national ad", "url": "https://www.quiverquant.com/news/LENZ+Therapeutics+Launches+Telehealth+Access+for+VIZZ+Alongside+National+TV+Campaign", "source_name": "Quiver Quantitative", "published_at": "2026-07-06T12:20:00", "published_display": "06 Jul 2026 12:20", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ - LENZ Therapeutics Inc Options", "summary": "This article provides comprehensive financial data for LENZ Therapeutics Inc. (LENZ), including its last closing price, market capitalization, income, sales, and various financial ratios. It also details insider and institutional ownership, stock performance metrics, and analyst ", "url": "https://finviz.com/stock?t=LENZ&p=m&ty=oc&b=2&r=y5&ov=list_strike&s=7.5", "source_name": "Finviz", "published_at": "2026-07-03T04:40:04", "published_display": "03 Jul 2026 04:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ)", "summary": "LENZ Therapeutics announced changes to its Board of Directors and Audit Committee following the resignation of director Zach Scheiner on June 30, 2026. Scheiner's departure was not due to any dispute, and the Board subsequently reduced its size to six members. Additionally, Jeff ", "url": "https://www.stocktitan.net/sec-filings/LENZ/8-k-lenz-therapeutics-inc-reports-material-event-35e417be9a1c.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:10:40", "published_display": "02 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article focuses on the \"Price to sales forward\" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It appears to be a financial data snippet from TradingView, providing an overview of the company's stock performance. The content includes general market information and links ", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T15:39:42", "published_display": "01 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides a brief financial update on LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its price-to-book forward ratio. The content indicates the market is currently closed, with no trades, and offers information on the company's financials, news, and ", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T02:39:13", "published_display": "01 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides financial information for LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial snapshot from TradingView, detailing various data points and market information relevant", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T04:10:34", "published_display": "30 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of LENZ Therapeutics, Inc. \u2013 NASDAQ:LENZ", "summary": "This article provides the \"Price to earnings forward\" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It's presented within the context of TradingView's financial data offerings for the company. The page focuses on a specific financial data point rather than a detailed analyti", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T02:09:38", "published_display": "30 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index", "summary": "LENZ Therapeutics, Inc. (NasdaqGS:LENZ), a biopharmaceutical company focused on developing treatments for presbyopia, has been added to the Russell Microcap Value Benchmark Index. This news follows a period of significant activity for the company, including recent license agreeme", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-added-to-russell-microcap-value-benchmark-index-ce7f5fdfdb8af020", "source_name": "marketscreener.com", "published_at": "2026-06-29T16:38:00", "published_display": "29 Jun 2026 16:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark", "summary": "LENZ Therapeutics, Inc. (NasdaqGS: LENZ) has been added to the Russell 2000 Value Benchmark Index. This news follows several recent updates for the biopharmaceutical company, including its addition to the Russell Microcap Value Benchmark and an exclusive licensing agreement for i", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-added-to-russell-2000-value-benchmark-ce7f5fdfd880f320", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:09:38", "published_display": "29 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "LENZ Therapeutics, Inc. (NasdaqGS:LENZ) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows a previous report that the company was also dropped from the Russell 3000 Growth Benchmark. The company, which is a pre-commercial stage biopharmaceutical ", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-nasdaqgs-lenz-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdede88f022", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T09:44:12", "published_display": "29 Jun 2026 09:44", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ)", "summary": "Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a shared voting and dispositive power over 1,603,512 shares, or 5.1%, of LENZ Therapeutics, Inc. Common Stock. This disclosure was made via a Schedule 13G filing, indicating a passiv", "url": "https://www.stocktitan.net/sec-filings/LENZ/schedule-13g-lenz-therapeutics-inc-passive-investment-disclosure-5-01a6539f771d.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:02", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ)", "summary": "This article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report details. The company's", "url": "https://www.tradingview.com/symbols/NASDAQ-LENZ/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:03", "published_display": "26 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst", "summary": "LENZ Therapeutics has signed an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its FDA-approved eye drop therapy, VIZZ, targeting presbyopia in Australia and New Zealand. This marks LENZ's fifth such international partnership, with an analyst", "url": "https://www.sahmcapital.com/news/content/lenz-therapeutics-eye-drug-profile-supports-blockbuster-opportunity-analyst-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-26T01:10:38", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand", "summary": "LENZ Therapeutics, Inc. has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia treatment, VIZZ, in Australia and New Zealand. LENZ Therapeutics will receive an upfront payment and a significant share of gross pr", "url": "https://www.marketscreener.com/news/lenz-therapeutics-inc-and-arrotex-pharmaceuticals-pty-ltd-announce-exclusive-license-and-commerci-ce7f5fd8dc80ff20", "source_name": "www.marketscreener.com", "published_at": "2026-06-25T12:11:19", "published_display": "25 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com", "summary": "LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to register and commercialize its presbyopia drug VIZZ in Australia and New Zealand. LENZ will receive an upfront payment and profit share from sales of VIZZ, a once-daily eye drop that received FDA approval i", "url": "https://za.investing.com/news/stock-market-news/lenz-licenses-presbyopia-drug-vizz-to-arrotex-for-australia-nz-93CH-4342014", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T02:41:35", "published_display": "25 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ\u2122 in Australia and New Zealand", "summary": "LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ\u2122 eye drops in Australia and New Zealand. This partnership will see Arrotex, Australia\u2019s largest pharmaceutical company, register and commercialize VIZZ, L", "url": "https://ir.lenz-tx.com/news-events/press-releases/detail/58/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-commercialization-agreement-for-vizzin-australia-and-new-zealand", "source_name": "LENZ Therapeutics", "published_at": "2026-06-25T01:40:21", "published_display": "25 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics signs exclusive VIZZ deal for Australia and New Zealand", "summary": "LENZ Therapeutics (NASDAQ:LENZ) has finalized an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its presbyopia treatment, VIZZ, in Australia and New Zealand. This partnership provides LENZ with an upfront payment and a significant share of gr", "url": "https://grafa.com/en/news/united-states/lenz-therapeutics-arrotex-vizz-license-australia-new-zealand", "source_name": "grafa.com", "published_at": "2026-06-24T16:40:38", "published_display": "24 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ", "summary": "LENZ Therapeutics, Inc. has entered into an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia drug, VIZZ, in Australia and New Zealand. LENZ will receive an upfront payment and a profit share from sales of VIZZ, a once-dail", "url": "https://www.investing.com/news/company-news/lenz-licenses-presbyopia-drug-vizz-to-arrotex-for-australia-nz-93CH-4758164", "source_name": "Investing.com", "published_at": "2026-06-24T13:40:38", "published_display": "24 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Arrotex Pharmaceuticals Announce", "summary": "LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ\u2122 in Australia and New Zealand. This agreement will allow Arrotex to register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for pre", "url": "https://www.globenewswire.com/news-release/2026/06/24/3316833/0/en/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-license-and-commercialization-agreement-for-vizz-in-australia-and-new-zealand.html", "source_name": "GlobeNewswire", "published_at": "2026-06-24T12:40:38", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ expands VIZZ beyond the U.S. with Australia, NZ deal", "summary": "LENZ Therapeutics has partnered with Arrotex Pharmaceuticals for the exclusive license and commercialization of VIZZ, their FDA-approved presbyopia eye drop, in Australia and New Zealand. This agreement is LENZ's fifth ex-U.S. commercialization deal for VIZZ and includes an upfro", "url": "https://www.stocktitan.net/news/LENZ/lenz-therapeutics-and-arrotex-pharmaceuticals-announce-exclusive-8yzvuv409ovj.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:39:39", "published_display": "24 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics (NasdaqGS:LENZ) Stock Forecast & Analyst Predictions", "summary": "LENZ Therapeutics (NasdaqGS:LENZ) is forecast to grow earnings and revenue significantly, but is expected to remain unprofitable for the next three years, with projected negative return on equity. Recent analyst revisions show decreased revenue forecasts and increased loss projec", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/future", "source_name": "Simply Wall Street", "published_at": "2026-06-24T12:39:39", "published_display": "24 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Inc (LENZ) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of LENZ Therapeutics Inc (LENZ), stating its current valuation score is 6.79, ranking it 297 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio is -1.74, significantly below its recent high", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lenz/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:57", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of LENZ Therapeutics Inc (LENZ), focusing on its support and resistance levels, key indicators, and moving averages. The stock's current price momentum score is 6.40, ranking it 263 out of 388 in its industry, and it is trading between a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-lenz/technical", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:57", "published_display": "18 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics adds China partner for presbyopia drug VIZZ", "summary": "", "url": "https://finance.yahoo.com/m/0753ae60-922c-3a72-a870-1d6137c9c4da/lenz-therapeutics-adds-china.html", "source_name": "Proactive", "published_at": "2026-06-08T15:33:00+00:00", "published_display": "08 Jun 2026 15:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics to Receive VIZZ Payments From Everest-Corxel Deal", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-receive-vizz-payments-080136167.html", "source_name": "MT Newswires", "published_at": "2026-06-08T08:01:36+00:00", "published_display": "08 Jun 2026 08:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ\u00ae (LNZ100) in Greater China", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-announces-everest-medicines-233000707.html", "source_name": "GlobeNewswire", "published_at": "2026-06-07T23:30:00+00:00", "published_display": "07 Jun 2026 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics and Everest Medicines Form Strategic Partnership for Development and Commercialization of VIZZ in Greater China | LENZ Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQMFNudDVLc1pmQUU1YzZTbm1UNzRVYWdoWFFreWFJMDZRSWtfNVdLbUdRNnN1cmxyZWlpWGxQaHZlMVNyVXF6NHNsYmVWRXNUcWtlUzlFemlLblR2bmlUd1BVcmdZQW1tejJmSDUyd1czS1Z3WTMwWDkxTjVjY1RQeHNieU85ZTQ2ZWVZRTB5TjRlWm1sOWIyUENiMEM2UTZnWlNhdTFib00zbjN2YTBMTXMwRzJSVHcyLTJCckh3T241Y3ptWVF3OVY4dFk1bjdUeDVNQnpZaFhTMFFiZ0RMekNXVGRlVktvXzhtU0Ffa1VVbm9o?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/lenz-therapeutics-participate-upcoming-investor-120000333.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOc25sWHE5ZmNLbFh2Q0JQSjZMWllCb2RYN0VoMGI5TEljMHpDc1ZGbnZrOERkYUx2TDYxUHd0VFpxZE52MXZ6Wk1yYjdTck5IWkFaQUM3NkFseEpUQWx2ampkUkZzRUZPa0paUkdGcWZhVTJKTmJ4bXdST2w1RUxwcFJfalpaMXNaSHNxaTNtVXRJbEtqbEVrV05HMzNkdUl1?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Some LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Just Made A Major Cut To Next Year's Estimates", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNV29hSU5Zd2oyQWNSV005OTNYSFp4RnpMYU1BSVZ3dUYzLWZPNGRaNVdLWklMcFZDVEhGZEhkc2lFSzVWN25PMmE4X0tMV216bUhmRWpMYnlPNzlRdlZJRUlDeG5ZaWdTLXJUQ09Od2U1czkyRThCSXlETGZCMWwwTXVrNzlYU09Uci1ObUdQQXAxb2NZS0JnUllGV2xYRjA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Are Trimming Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxOZHJ0NFY5Ymc3Z2VGd2tSRGVIMGpnSG0yOTVkamVwZm1KU0RSSkx5RUtsUnh4M1RoMUtjeFlKQU5IZG9zMUwwS3Y1NUhpaE81Z1JRSGEwWkQyUUN6RUtzcWwzbnlpaWl5WnFLWGhQUmFJc3p1MUNqN3JGSFIzbGlHS3BReWN5S2VmV1pYXzdLazk4b0k1SlB1c21IQ1ZqV2tRYUQwdHNTcURwMVVaQW8xN1JmcmdKcE9DaTVLZU9VcXlaRjNVb3pjUDd4Ni1YTVlacU9jQVJIMXVCaG1mM042OFQ3bHdteXFqMkE?oc=5", "source_name": "LENZ Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ THERAPEUTICS ($LENZ) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNQjlDaGI4MEpmMWxWRlluYzduZmE4NTdZVlFGaGV0NGUxNXIxcU54Vkh4WWxPaHpjTWF1MDBTcnlzUmJXS1RfTlB3Y1NrTDRRU3hpNW80WTQ2eWpxaWZpZmc4N0ZqSWJYSE5ZZVZwQ2tuRVNCSFlVZnVrLUtJYkk1RUVhb0dkcDlGaldkOGRVX2Ita21t?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPR2RsdHJDQWVjYk9iaGFWQ0I2SjdHQ05HV2w1S09VclU4OWU2Qzk2VXU4WjdwZmd4TWt5eldmcDhWVnFFdld5ZnN0TG9ZVnRKSlBXVVpNRU91VzN1Z3E3SDlsdk5ESFY4QzhWUlNSZzdHd0plSW1zYXM5OXVoRTE4MmoxV0JmUTlVdmNGd3dUY2pqVXhPTHFmQnpBc1phdmQ3X0FxRXVR?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics: Speculative But Strong Buy (NASDAQ:LENZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOS2VLNFdLamNidU9EaVc3NnVrZEFMQk1WUUpfbktiMFUxNkNDcXNxUHdTbU5HV1dHaVZJVXJuV0xwNms1c0N4TnNhZzVhWklNUTdEZi1GWVA2bGZSSER2ZFVzUlJxTkVMN2l6ejNxUmZoZ2FNSUZkUVlGNFJJUGo2XzFZWVdvMS1UOXBKWU5B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of LENZ Therapeutics Picks Up 57% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNMlFsVDVnZzc0Q0o5NEt4RmdJTjk1ZTYtLVpIaVgzTGt6R0g1UzV6cFNVamdsVmVpT3VrT1d2SlpRWHI0YkNmaS1CVnN2cTZiX09manpvc2YtemluY0ZFYW5YSHEyd1ZIYXd0NEVMdDRMdWgxM0kwazgxb0ctT1Mta3Yyd29ZMU9JSEZBeFBQNDZRVjc4WVhzaV9ZYUxhRGhtbE5F?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "President of LENZ Therapeutics Evert Schimmelpennink Buys 57% More Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxObEFWWU4yLUJMMndaaS1aeTEtdWQzX1d2elpabmw2dWpkQkZmMFpyVjB4SjVKMFhmMWI0QUU2bEZ5Wm8wUHhWX2N6N0R3c2JEUUZ5aW1vSy1kS0VHN0kzQ1RCSWM4SWhsVzhaQkJ0NUFEQmsyMlpqYXhYcUp4VERRQTB5MmZRZUNqUVVjTE16ZlRMVnNicXJZ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-27T07:00:00+00:00", "published_display": "27 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics (LENZ) Loss Deepens As VIZZ Launch Tests Bullish Growth Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Lenz Therapeutics Stock Crashed Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNVnBaSHV1NzBaN2xQWTNBc18tS1Y1Tml4emVWQ0d0Q1pqaDl1c1c2Q0pwNzNHRUd0MmZFc2lpeFphVjFHaldGMjBteHhHNDNlaDlVdlhfeHZOM1ctcDhlU1ktV24yZUQ3SllyWnFCT24yRkZxSGhsd3pWYlNPaXlGdHhfNUJ2d1pFUDB6Zw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At LENZ Therapeutics (LENZ) Valuation After New Middle East VIZZ Distribution Agreement", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAJBVV95cUxOUmhsbmg0TzF5NjJXbHctWWV1aEdfZVJMU3pyYmdQaEJncnhMSlgxaDhWSDJEempZQWxab0dHNldHd0hTQ2ppdHMwVjZqaEw2MENncTVGMThCTGxrOFNNLXhDamFnb0k2TkNJXzNYQ1NsMkVTTFQ0OVo3UHFDbk0zUUlaNWVMNndnZWlHMzN4eGxDQ0ZnMXNWVm9pQ1BLZ25BX2ptVHZXUXRtQmFXM296bUdKazMyUk1uMGlRY0R5QW9IcGdyRXB6TzJSaEhFZGZUaUZEWVN3UkMyYjZ2WHg2WldSbWhnVUxKelZobGRfMTZtQ1hVdExyamM4RXNFc0xuYVFJaw?oc=5", "source_name": "LENZ Therapeutics", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LENZ Therapeutics: Was That A Market Overreaction? (NASDAQ:LENZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxOMTZyS2ZObm9XeFhhMW5ZZllscnZNeHNZUmNTUHhMQjE5M2NnQ25qaldfblNCZXV2S0JBYUtJN2FFbmpoak1zRXctSlpTNXJqdWZ2LWtuT042YnBwN1V6SEdlbHlUY1FRMno4MjBENmt4RjA2ODAwbE8tTU92Zjk2dmxqeHFfWUZyUmZqamV3MHpxVUU?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 65, "sentiment_summary": {"positive": 16, "negative": 10, "neutral": 39, "score": 54, "total": 65, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.85, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 10.31, "count": 21}, {"event": "deals", "label": "Deals and strategy", "weight": 3.3, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 16, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 5.59, "latest_week": "2026-07-10", "one_week_move": -5.1, "four_week_move": -17.4, "twelve_week_move": -45.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.087961, "market_dynamics_buy_signal": false, "relative_strength": -77.830647, "fair_value_gap": -73.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.089, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.1% over one week, -17.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "simplywall.st", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "LENZ Therapeutics", "count": 4}, {"label": "Stock Titan", "count": 4}, {"label": "Quiver Quantitative", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 21}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.1% over one week, -17.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely"}], "updated_at": "2026-07-18T03:16:03.038387+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}